Oncolytic Virotherapy for Hematological Malignancies
Hematological malignancies such as leukemias, lymphomas, multiple myeloma (MM), and the myelodysplastic syndromes (MDSs) primarily affect adults and are difficult to treat. For high-risk disease, hematopoietic stem cell transplant (HCT) can be used. However, in the setting of autologous HCT, relapse...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Virology |
| Online Access: | http://dx.doi.org/10.1155/2012/186512 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560812716195840 |
|---|---|
| author | Swarna Bais Eric Bartee Masmudur M. Rahman Grant McFadden Christopher R. Cogle |
| author_facet | Swarna Bais Eric Bartee Masmudur M. Rahman Grant McFadden Christopher R. Cogle |
| author_sort | Swarna Bais |
| collection | DOAJ |
| description | Hematological malignancies such as leukemias, lymphomas, multiple myeloma (MM), and the myelodysplastic syndromes (MDSs) primarily affect adults and are difficult to treat. For high-risk disease, hematopoietic stem cell transplant (HCT) can be used. However, in the setting of autologous HCT, relapse due to contamination of the autograft with cancer cells remains a major challenge. Ex vivo manipulations of the autograft to purge cancer cells using chemotherapies and toxins have been attempted. Because these past strategies lack specificity for malignant cells and often impair the normal hematopoietic stem and progenitor cells, prior efforts to ex vivo purge autografts have resulted in prolonged cytopenias and graft failure. The ideal ex vivo purging agent would selectively target the contaminating cancer cells while spare normal stem and progenitor cells and would be applied quickly without toxicities to the recipient. One agent which meets these criteria is oncolytic viruses. This paper details experimental progress with reovirus, myxoma virus, measles virus, vesicular stomatitis virus, coxsackievirus, and vaccinia virus as well as requirements for translation of these results to the clinic. |
| format | Article |
| id | doaj-art-6fc058bfe3134746b94e8d9ff0b1d213 |
| institution | Kabale University |
| issn | 1687-8639 1687-8647 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Virology |
| spelling | doaj-art-6fc058bfe3134746b94e8d9ff0b1d2132025-02-03T01:26:37ZengWileyAdvances in Virology1687-86391687-86472012-01-01201210.1155/2012/186512186512Oncolytic Virotherapy for Hematological MalignanciesSwarna Bais0Eric Bartee1Masmudur M. Rahman2Grant McFadden3Christopher R. Cogle4Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, ARB R4-202, P.O. Box 100278, Gainesville, FL 32610-0278, USADepartment of Molecular Genetics and Microbiology, College of Medicine, University of Florida, ARB R4-295, P.O. Box 100266, Gainesville, FL 32610, USADepartment of Molecular Genetics and Microbiology, College of Medicine, University of Florida, ARB R4-295, P.O. Box 100266, Gainesville, FL 32610, USADepartment of Molecular Genetics and Microbiology, College of Medicine, University of Florida, ARB R4-295, P.O. Box 100266, Gainesville, FL 32610, USADivision of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, ARB R4-202, P.O. Box 100278, Gainesville, FL 32610-0278, USAHematological malignancies such as leukemias, lymphomas, multiple myeloma (MM), and the myelodysplastic syndromes (MDSs) primarily affect adults and are difficult to treat. For high-risk disease, hematopoietic stem cell transplant (HCT) can be used. However, in the setting of autologous HCT, relapse due to contamination of the autograft with cancer cells remains a major challenge. Ex vivo manipulations of the autograft to purge cancer cells using chemotherapies and toxins have been attempted. Because these past strategies lack specificity for malignant cells and often impair the normal hematopoietic stem and progenitor cells, prior efforts to ex vivo purge autografts have resulted in prolonged cytopenias and graft failure. The ideal ex vivo purging agent would selectively target the contaminating cancer cells while spare normal stem and progenitor cells and would be applied quickly without toxicities to the recipient. One agent which meets these criteria is oncolytic viruses. This paper details experimental progress with reovirus, myxoma virus, measles virus, vesicular stomatitis virus, coxsackievirus, and vaccinia virus as well as requirements for translation of these results to the clinic.http://dx.doi.org/10.1155/2012/186512 |
| spellingShingle | Swarna Bais Eric Bartee Masmudur M. Rahman Grant McFadden Christopher R. Cogle Oncolytic Virotherapy for Hematological Malignancies Advances in Virology |
| title | Oncolytic Virotherapy for Hematological Malignancies |
| title_full | Oncolytic Virotherapy for Hematological Malignancies |
| title_fullStr | Oncolytic Virotherapy for Hematological Malignancies |
| title_full_unstemmed | Oncolytic Virotherapy for Hematological Malignancies |
| title_short | Oncolytic Virotherapy for Hematological Malignancies |
| title_sort | oncolytic virotherapy for hematological malignancies |
| url | http://dx.doi.org/10.1155/2012/186512 |
| work_keys_str_mv | AT swarnabais oncolyticvirotherapyforhematologicalmalignancies AT ericbartee oncolyticvirotherapyforhematologicalmalignancies AT masmudurmrahman oncolyticvirotherapyforhematologicalmalignancies AT grantmcfadden oncolyticvirotherapyforhematologicalmalignancies AT christopherrcogle oncolyticvirotherapyforhematologicalmalignancies |